A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Inclusion Criteria:

1. Participants of any sex and gender must be ≥ 18 years of age at the time of signingthe informed consent.

2. Participants with eGFR ≥ 30 and < 90 mL/min/1.73 m2 at screening

3. Participants with UACR > 200 mg/g (22.6 mg/mmol) and < 5000 mg/g (565 mg/mmol) atscreening

4. Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg atthe randomisation visit.

5. Stable and maximum daily tolerated dose of either an ACE inhibitor or an ARB (notboth) for at least 4 weeks prior to the screening visit, if not medicallycontraindicated.

6. Participants with:

7. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2.

8. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR < 45 mL/min/1.73 m2.

9. Contraceptive use should be consistent with local regulations regarding the methodsof contraception for those participating in clinical studies. Applicable to femaleparticipants.

Exclusion Criteria:

1. Systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg atscreening.

2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months beforescreening

3. Serum sodium < 135 mmol/L at the Screening Visit (values obtained within 4 weeksprior to screening or at the Screening Visit).

4. Diabetes mellitus:

5. T1DM at the screening visit

6. Uncontrolled T2DM at screening: HbA1C > 10.5% (> 91 mmol/mol)

7. New York Heart Association functional HF class IV at screening

8. Any use of mineralocorticoid receptor antagonists (such as spironolactone,eplerenone, or finerenone), aldosterone synthase inhibitors, potassium-sparingdiuretics (such as triamterene or amiloride), or potassium binders (such as sodiumzirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeksprior to screening

9. Stroke, transient ischaemic cerebral attack, valve implantation or valvereplacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, orhospitalisation for worsening HF within previous 3 months prior to randomisation.

10. Known severe hepatic impairment, defined as Child-Pugh Class C, based on recordsthat confirm documented medical history.

11. Documented history of adrenal insufficiency.

12. Any dialysis (including for acute kidney injury) within 3 months prior to thescreening

13. Any acute kidney injury within 3 months prior to the screening visit.

14. Prohibited concomitant medications